Valerio Therapeutics (XPAR:ALVIO) Short Interest


XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
25 GF Score
Price €0.51
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:ALVIO vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Valerio Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Short Interest falls into.


XPAR:ALVIO
25GF Score
Valerio Therapeutics XPAR:ALVIO
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Short Interest:
  • GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
  • GF Score™: 25/100 with 9 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
25GF Score

Get the complete analysis for XPAR:ALVIO

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.07
GF Value